Cargando…

Tetrandrine Prevents Bone Loss in Ovariectomized Mice by Inhibiting RANKL-Induced Osteoclastogenesis

Postmenopausal osteoporosis (PMOP) is a metabolic bone disease characterized by decreased bone density and strength due to the imbalance between osteogenesis and osteoclastogenesis. Postmenopausal estrogen withdrawal increases proinflammatory cytokines and increases the serum level of Receptor activ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Zeyuan, Qian, Zhi, Zhang, Xu, Chen, Fancheng, Ni, Shuo, Kang, Zhanrong, Zhang, Fangxue, Li, Dejian, Yu, Baoqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967024/ https://www.ncbi.nlm.nih.gov/pubmed/31998129 http://dx.doi.org/10.3389/fphar.2019.01530

Ejemplares similares

Cytisine attenuates bone loss of ovariectomy mouse by preventing RANKL‐induced osteoclastogenesis
por: Qian, Zhi, et al.
Publicado: (2020)

Juglanin Inhibits Osteoclastogenesis in Ovariectomized Mice via the Suppression of NF-κB Signaling Pathways
por: Zhang, Fangxue, et al.
Publicado: (2021)

Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis
por: Li, Chang-hong, et al.
Publicado: (2021)

Corrigendum: Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis
por: Li, Chang-hong, et al.
Publicado: (2023)

Betulinic Acid Protects From Bone Loss in Ovariectomized Mice and Suppresses RANKL-Associated Osteoclastogenesis by Inhibiting the MAPK and NFATc1 Pathways
por: Wei, Jiyong, et al.
Publicado: (2020)

Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
por: Yang, Xue, et al.
Publicado: (2021)

Finite element analysis of dual small plate fixation and single plate fixation for treatment of midshaft clavicle fractures
por: Zhang, Fangxue, et al.
Publicado: (2020)

Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis
por: Chen, Xiao, et al.
Publicado: (2017)

Schisandrin A restrains osteoclastogenesis by inhibiting reactive oxygen species and activating Nrf2 signalling
por: Ni, Shuo, et al.
Publicado: (2020)

Tetrandrine inhibits RANKL-induced osteoclastogenesis by promoting the degradation of TRAIL
por: Li, Jiarui, et al.
Publicado: (2022)

BCI Suppresses RANKL-Mediated Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss
por: Cai, Chenhui, et al.
Publicado: (2021)

Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice
por: Zhan, Yunfei, et al.
Publicado: (2020)

Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss
por: Qi, Dahu, et al.
Publicado: (2021)

PRMT1 mediates RANKL-induced osteoclastogenesis and contributes to bone loss in ovariectomized mice
por: Choi, Joo-Hee, et al.
Publicado: (2018)

Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis
por: Jin, Haiming, et al.
Publicado: (2019)

Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
por: Qi, Guobin, et al.
Publicado: (2022)

Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-κB and MAPK activation
por: Guo, Wen, et al.
Publicado: (2021)

The Molecular Mechanisms Study of Engeletin Suppresses RANKL-Induced Osteoclastogenesis and Inhibits Ovariectomized Murine Model Bone Loss
por: Feng, Mingzhe, et al.
Publicado: (2023)

Theaflavin-3, 3′-Digallate Suppresses RANKL-Induced Osteoclastogenesis and Attenuates Ovariectomy-Induced Bone Loss in Mice
por: Ai, Zexin, et al.
Publicado: (2020)

Nardosinone Suppresses RANKL-Induced Osteoclastogenesis and Attenuates Lipopolysaccharide-Induced Alveolar Bone Resorption
por: Niu, Chenguang, et al.
Publicado: (2017)

Anemonin Attenuates RANKL-Induced Osteoclastogenesis and Ameliorates LPS-Induced Inflammatory Bone Loss in Mice via Modulation of NFATc1
por: Hou, Huanhuan, et al.
Publicado: (2020)

Celastrol Attenuates RANKL-Induced Osteoclastogenesis in vitro and Reduces Titanium Particle-Induced Osteolysis and Ovariectomy-Induced Bone Loss in vivo
por: Xu, Qiang, et al.
Publicado: (2021)

The role played by ailanthone in inhibiting bone metastasis of breast cancer by regulating tumor-bone microenvironment through the RANKL-dependent pathway
por: Wang, Yajun, et al.
Publicado: (2023)

Hesperetin Prevents Bone Resorption by Inhibiting RANKL-Induced Osteoclastogenesis and Jnk Mediated Irf-3/c-Jun Activation
por: Zhang, Qiang, et al.
Publicado: (2018)

Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 Pathways
por: Wang, Gang, et al.
Publicado: (2022)

Schisandrin B Inhibits Osteoclastogenesis and Protects Against Ovariectomy-Induced Bone Loss
por: Wang, Jia, et al.
Publicado: (2020)

Parkin Inhibits RANKL-Induced Osteoclastogenesis and Ovariectomy-Induced Bone Loss
por: Hou, Weiduo, et al.
Publicado: (2022)

Bushen huoxue decoction inhibits RANKL-stimulated osteoclastogenesis and glucocorticoid-induced bone loss by modulating the NF-κB, ERK, and JNK signaling pathways
por: Liu, Yamei, et al.
Publicado: (2022)

Corrigendum: Bushen huoxue decoction inhibits RANKL-stimulated osteoclastogenesis and glucocorticoid-induced bone loss by modulating the NF-κB, ERK, and JNK signaling pathways
por: Liu, Yamei, et al.
Publicado: (2023)

Apigenin inhibits osteoblastogenesis and osteoclastogenesis and prevents bone loss in ovariectomized mice
por: Goto, Tadashi, et al.
Publicado: (2014)

Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways
por: Zhi, Xin, et al.
Publicado: (2020)

12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation
por: He, Qi, et al.
Publicado: (2022)

Tectorigenin inhibits RANKL‐induced osteoclastogenesis via suppression of NF‐κB signalling and decreases bone loss in ovariectomized C57BL/6
por: Ma, Chiyuan, et al.
Publicado: (2018)

Baohuoside I Inhibits Osteoclastogenesis and Protects Against Ovariectomy-Induced Bone Loss
por: Ma, Min, et al.
Publicado: (2022)

Evodiamine inhibits RANKL‐induced osteoclastogenesis and prevents ovariectomy‐induced bone loss in mice
por: Jin, Haiming, et al.
Publicado: (2018)

Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo
por: Peng, Jiaxuan, et al.
Publicado: (2020)

Poria Cocos Ameliorates Bone Loss in Ovariectomized Mice and Inhibits Osteoclastogenesis In Vitro
por: Hwang, Youn-Hwan, et al.
Publicado: (2020)

Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR
por: Huang, Jun-ming, et al.
Publicado: (2018)

Monascin abrogates RANKL-mediated osteoclastogenesis in RAW264.7 cells via regulating MAPKs signaling pathways
por: Cheng, Yin, et al.
Publicado: (2022)

Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities
por: Liu, Yuhao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_elk6k07n7k1okqbac5ht1ka7bk